Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Immune diseases, Rare diseases

Aliases & Classifications for Vasculitis

MalaCards integrated aliases for Vasculitis:

Name: Vasculitis 12 73 20 58 29 54 6 42 44 15 62 17 70
Autoimmune Vasculitis 20 70
Angiitis 12 20
Vasculitis, Autoimmune 20
Systemic Vasculitis 58


Orphanet: 58  
Rare circulatory system diseases
Rare systemic and rhumatological diseases

External Ids:

Disease Ontology 12 DOID:865
MeSH 44 D014657
NCIt 50 C26912
SNOMED-CT 67 195375002
MESH via Orphanet 45 D014657 D056647
UMLS via Orphanet 71 C0042384 C0264939
Orphanet 58 ORPHA52759
UMLS 70 C0042384 C1328843

Summaries for Vasculitis

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 52759 Definition Vasculitis represents a clinically heterogenous group of diseases of multifactorial etiology characterized by inflammation of either large-sized vessels (large-vessel vasculitis, e.g. Giant- cell arteritis and Takayasu arteritis; see these terms), medium-sized vessels (medium-vessel vasculitis e.g. polyarteritis nodosa and Kawasaki disease; see these terms), or small-sized vessels (small-vessel vasculitis, e.g. granulomatosis with polyangiitis, microscopic polyangiitis, immunoglobulin A vasculitis, and cutaneous leukocytoclastic angiitis; see these terms). Vasculitis occurs at any age, may be acute or chronic, and manifests with general symptoms such as fever, weight loss and fatigue, as well as more specific clinical signs depending on the type of vessels and organs affected. The degree of severity is variable, ranging from life or sight threatening disease (e.g. Behcet disease, see this term) to relatively minor skin disease.

MalaCards based summary : Vasculitis, also known as autoimmune vasculitis, is related to anca-associated vasculitis and hypersensitivity vasculitis, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Vasculitis is PRTN3 (Proteinase 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Innate Immune System. The drugs Prednisone and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, skin and endothelial, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A vascular disease that is characterized by inflammation of the blood vessels.

MedlinePlus : 42 Vasculitis is an inflammation of the blood vessels. It happens when the body's immune system attacks the blood vessel by mistake. It can happen because of an infection, a medicine, or another disease. The cause is often unknown. Vasculitis can affect arteries, veins and capillaries. Arteries are vessels that carry blood from the heart to the body's organs. Veins are the vessels that carry blood back to the heart. Capillaries are tiny blood vessels that connect the small arteries and veins. When a blood vessel becomes inflamed, it can Narrow, making it more difficult for blood to get through Close off completely so that blood can't get through Stretch and weaken so much that it bulges. The bulge is called an aneurysm. If it bursts, it can cause dangerous bleeding inside the body. Symptoms of vasculitis can vary, but usually include fever, swelling and a general sense of feeling ill. The main goal of treatment is to stop the inflammation. Steroids and other medicines to stop inflammation are often helpful. NIH: National Heart, Lung, and Blood Institute

PubMed Health : 62 About vasculitis: Vasculitis (vas-kyu-LI-tis) is a condition that involves inflammation in the blood vessels. The condition occurs if your immune system attacks your blood vessels by mistake. This may happen as the result of an infection, a medicine, or another disease or condition. “Inflammation” refers to the body’s response to injury, including injury to the blood vessels. Inflammation may involve pain, redness, warmth, swelling, and loss of function in the affected tissues. In vasculitis, inflammation can lead to serious problems. Complications depend on which blood vessels, organs, or other body systems are affected.

Wikipedia : 73 Vasculitis is a group of disorders that destroy blood vessels by inflammation. Both arteries and veins... more...

Related Diseases for Vasculitis

Diseases in the Vasculitis family:

Autoimmune Vasculitis Secondary Vasculitis

Diseases related to Vasculitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1795)
# Related Disease Score Top Affiliating Genes
1 anca-associated vasculitis 33.2 SERPINA1 PRTN3 MPO
2 hypersensitivity vasculitis 33.1 TNF PRTN3 MPO MEFV CRP
3 livedoid vasculitis 32.9 APOH ADA2
4 churg-strauss syndrome 32.9 TNF THBD PRTN3 MPO
5 rheumatoid vasculitis 32.8 VCAM1 TNF SELE ICAM1 CX3CL1
6 allergic cutaneous vasculitis 32.8 PRTN3 MPO
7 henoch-schoenlein purpura 32.7 VCAM1 PRTN3 MPO MEFV ICAM1 CRP
8 central nervous system vasculitis 32.7 TNFSF13B TNF PRTN3 MPO CRP
9 kawasaki disease 32.6 TNF SELE ELANE CRP
10 autoimmune vasculitis 32.3 TNF PRTN3 MPO ELANE CRP
11 granulomatosis with polyangiitis 32.2 TNF SERPINB1 SERPINA1 SELE PRTN3 MPO
12 polyarteritis nodosa 32.2 VCAM1 SELE PRTN3 MPO MEFV ICAM1
13 rapidly progressive glomerulonephritis 32.1 PRTN3 MPO ICAM1 ELANE CRP
14 granulomatous angiitis 32.1 PRTN3 CRP
15 arthus reaction 32.1 TNF ICAM1 ELANE
16 temporal arteritis 32.0 TNF PRTN3 MPO CRP CD40LG APOH
17 takayasu arteritis 32.0 VCAM1 TNF THBD SELE ICAM1 CRP
18 pyoderma gangrenosum 32.0 TNF MEFV APOH
19 buerger disease 32.0 VCAM1 ICAM1 CRP APOH
20 alpha-1-antitrypsin deficiency 31.7 TNF SERPINB1 SERPINA1 PRTN3 MPO ELANE
21 exanthem 31.7 TNF PRTN3 MEFV CRP
22 purpura 31.6 VWF TNFSF13B TNF THBD MEFV CRP
23 glomerulonephritis 31.5 VCAM1 PRTN3 MPO ICAM1 ELANE CTSG
24 end stage renal disease 31.5 TNF THBD ICAM1 CRP
25 crescentic glomerulonephritis 31.4 VCAM1 SELE PRTN3 MPO ICAM1 CTSG
26 mononeuritis multiplex 31.4 TNF PRTN3 MPO CRP ADA2
27 aortitis 31.3 TNF PRTN3 MPO CRP
28 cryoglobulinemia 31.3 TNFSF13B TNF CD40LG APOH
29 endocarditis 31.3 VCAM1 TNF CRP APOH
30 panniculitis 31.3 TNF SERPINA1 CRP
31 neutropenia 31.2 TNF MPO ELANE CRP
32 erythema nodosum 31.2 VCAM1 TNF SELE ICAM1 CRP
33 infective endocarditis 31.2 TNF CRP APOH
34 interstitial lung disease 31.2 TNF PRTN3 ICAM1 CRP
35 otitis media 31.2 TNF MPO ICAM1 CRP
36 crohn's disease 31.1 TNF MPO MEFV ICAM1 CRP
37 enthesopathy 31.1 TNF MEFV CRP
38 mononeuropathy 31.1 TNF PRTN3 MPO CRP
39 scleritis 31.1 TNF SELE PRTN3 MPO CRP
40 vascular disease 31.1 VWF VCAM1 TNF THBD SELE MPO
41 systemic lupus erythematosus 31.1 VWF VCAM1 TNFSF13B TNF THBD SELE
42 brucellosis 31.1 TNF MPO MEFV CRP
43 pyoderma 31.1 TNF MEFV CRP APOH
44 connective tissue disease 31.1 TNFSF13B TNF CRP CD40LG APOH
45 ulcerative colitis 31.1 TNF PRTN3 MPO ICAM1 CTSG CRP
46 goodpasture syndrome 31.0 VCAM1 PRTN3 MPO
47 pericarditis 31.0 TNF MEFV CRP
48 arthritis 31.0 VCAM1 TNFSF13B TNF MEFV ICAM1 CRP
49 chorioretinitis 30.9 TNF CX3CL1 CRP
50 respiratory failure 30.9 TNF THBD SERPINA1 MPO ICAM1 ELANE

Graphical network of the top 20 diseases related to Vasculitis:

Diseases related to Vasculitis

Symptoms & Phenotypes for Vasculitis

UMLS symptoms related to Vasculitis:

angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Vasculitis:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 CD40LG CTSG CX3CL1 ELANE ICAM1 MEFV
2 homeostasis/metabolism MP:0005376 10 APOH CD40LG CRP CX3CL1 ELANE ICAM1
3 immune system MP:0005387 9.86 CD40LG CRP CTSG CX3CL1 ELANE ICAM1
4 mortality/aging MP:0010768 9.47 APOH CD40LG CTSG ELANE ICAM1 MEFV

Drugs & Therapeutics for Vasculitis

PubMed Health treatment related to Vasculitis: 62

Treatment for vasculitis will depend on the type of vasculitis you have, which organs are affected, and the severity of the condition. People who have severe vasculitis are treated with prescription medicines. Rarely, surgery may be done. People who have mild vasculitis may find relief with over-the-counter pain medicines, such as acetaminophen , aspirin , ibuprofen , or naproxen . The main goal of treating vasculitis is to reduce inflammation in the affected blood vessels . This usually is done by reducing or stopping the immune response that caused the inflammation.

Drugs for Vasculitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Mycophenolic acid Approved Phase 4 24280-93-1 446541
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
Hydroxychloroquine Approved Phase 4 118-42-3 3652
Povidone Approved Phase 4 9003-39-8 131751496
Azathioprine Approved Phase 4 446-86-6 2265
7 Antibiotics, Antitubercular Phase 4
8 Antitubercular Agents Phase 4
9 Adrenocorticotropic Hormone Phase 4
10 Melanocyte-Stimulating Hormones Phase 4
11 beta-Endorphin Phase 4
12 Tin Fluorides Phase 4
13 Immunoglobulins Phase 4
14 Antibodies Phase 4
15 Antineoplastic Agents, Immunological Phase 4
16 Immunologic Factors Phase 4
17 Antirheumatic Agents Phase 4
18 Immunosuppressive Agents Phase 4
19 Antimetabolites Phase 4
Alendronate Approved Phase 2, Phase 3 121268-17-5, 66376-36-1 2088
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
belimumab Approved Phase 3 356547-88-1 5957 10451420
Ranibizumab Approved Phase 2, Phase 3 347396-82-1 459903
Benralizumab Approved, Investigational Phase 3 1044511-01-4
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
Acetaminophen Approved Phase 3 103-90-2 1983
Clemastine Approved, Investigational Phase 3 15686-51-8 26987
Ibuprofen Approved Phase 3 15687-27-1 3672
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Infliximab Approved Phase 3 170277-31-3
Colchicine Approved Phase 3 64-86-8 6167 2833
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
Leuprolide Approved, Investigational Phase 3 53714-56-0 3911 657181
Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1 33036
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
41 Anti-Infective Agents Phase 3
42 Anti-Bacterial Agents Phase 3
43 Cyclosporins Phase 3
44 Calcineurin Inhibitors Phase 3
45 Antifungal Agents Phase 3
46 Plasma Substitutes Phase 3
47 interferons Phase 3
48 Interferon alpha-2 Phase 3
49 Interferon-alpha Phase 3
50 Angiogenesis Inhibitors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 197)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy Unknown status NCT01405807 Phase 4 Alemtuzumab
3 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 Patients Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
4 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
5 Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
6 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. Completed NCT03762824 Phase 4
7 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
8 Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial Recruiting NCT04316494 Phase 4 Hydroxychloroquine;Placebo
9 MAINtenance of Remission With RITuximab Versus Azathioprine for Patients With Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Prospective, Randomized, Controlled, Double-blind Study: the MAINRITSEG Trial Recruiting NCT03164473 Phase 4 Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
10 Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare Recruiting NCT02749292 Phase 4 Rituximab
11 Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis Recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
12 Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial Active, not recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
13 Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Terminated NCT02626845 Phase 4 Rituximab
14 Prevention of Relapses in PR3-ANCA-associated Vasculitis, a Tailored Approach Terminated NCT00128895 Phase 4 azathioprine
15 Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study Unknown status NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
16 Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
17 Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial Unknown status NCT02433522 Phase 3 rituximab;Placebo
18 Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
19 An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis Completed NCT01697267 Phase 3 Azathioprine
20 A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis. Completed NCT00414128 Phase 2, Phase 3 mycophenolate mofetil;cyclophosphamide
21 Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis Completed NCT00277251 Phase 2, Phase 3 Alendronate
22 A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine Completed NCT02994927 Phase 3 CCX168;Prednisone;Cyclophosphamide;Azathioprine
23 Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
24 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
25 Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial Completed NCT00987389 Phase 3 Glucocorticoids [Standard Dose];Glucocorticoids [Reduced Dose]
26 Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI) Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
27 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
28 Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
29 A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard of Care Therapy Completed NCT02020889 Phase 3 Placebo
30 Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
31 A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT01663623 Phase 3 Azathioprine
32 The Use of a VEGF Inhibitor (Lucentis) in Refractory Macular Edema Due to Eales' Disease Completed NCT00384449 Phase 2, Phase 3 Ranibizumab
33 Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE) Recruiting NCT02108860 Phase 3 Abatacept;placebo
34 The Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence Approach Recruiting NCT01940094 Phase 3 5 mg Prednisone;0 mg Prednisone
35 Evaluating Favorable, Immunological Effects of Rituximab With Cyclophosphamide Compared to Rituximab Alone in AAV Patients Recruiting NCT03942887 Phase 3 Rituximab;endoxan;Methylprednisolone;Prednisolone
36 Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial Recruiting NCT03323476 Phase 3 Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
37 A Randomized, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy Recruiting NCT04157348 Phase 3
38 The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach Active, not recruiting NCT01933724 Phase 3 5 mg prednisone;0 mg prednisone
39 The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children Attending Assiut University Hospital. Active, not recruiting NCT03692416 Phase 3 Ibuprofen;Prednisone;Methotrexate
40 Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides Active, not recruiting NCT02117453 Phase 3 Rosuvastatin;Placebo
41 Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Not yet recruiting NCT03920722 Phase 3 Rituximab;placebo
42 Evaluation of Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis Not yet recruiting NCT04008316 Phase 3 Colchicine
43 Multicenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease. ITAC : Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease Not yet recruiting NCT03371095 Phase 3 Infliximab;Cyclophosphamide
44 Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
45 GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases Terminated NCT01257802 Phase 3 depot leuprolide acetate 3.75 mg;Placebo
46 Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener's Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
47 Randomised Trial of Plasma Exchange or High Dose Methyl Prednisolone as Adjunctive Therapy for Severe Renal Vasculitis Terminated NCT01408836 Phase 2, Phase 3 Intravenous methyl prednisolone;Methyl prednisolone
48 PROphylaxis for paTiEnts at Risk of COVID-19 infecTion (PROTECT): a Basket Trial of Prophylactic Interventions Amongst At-risk Patients Withdrawn NCT04389359 Phase 2, Phase 3 Hydroxychloroquine Sulfate 200 MG
49 Acquired Immunodeficiency in ANCA (Antineutrophil Cytoplasmic Antibody) Associated Vasculitis Unknown status NCT03514979 Phase 2
50 Open-Label, to Evaluate the Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study: RITE Study Unknown status NCT02947945 Phase 2 Reslizumab

Search NIH Clinical Center for Vasculitis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cochrane evidence based reviews: vasculitis

Genetic Tests for Vasculitis

Genetic tests related to Vasculitis:

# Genetic test Affiliating Genes
1 Vasculitis 29

Anatomical Context for Vasculitis

MalaCards organs/tissues related to Vasculitis:

Neutrophil, Skin, Endothelial, T Cells, Heart, Eye, Spinal Cord

Publications for Vasculitis

Articles related to Vasculitis:

(show top 50) (show all 30070)
# Title Authors PMID Year
Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID-19 from influenza pneumonia. 42
33217134 2021
The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection. 42
33291346 2020
Rivaroxaban improves vascular response in LPS-induced acute inflammation in experimental models. 42
33301454 2020
Osteopontin in antineutrophil cytoplasmic autoantibody-associated vasculitis: relation to disease activity, organ manifestation and immunosuppressive therapy. 54 61
20424002 2010
Structures of human proteinase 3 and neutrophil elastase--so similar yet so different. 54 61
20423453 2010
New developments in lung endothelial heterogeneity: Von Willebrand factor, P-selectin, and the Weibel-Palade body. 61 54
20490980 2010
Late onset of pANCA renal and pulmonary vasculitis in a girl affected by undifferentiated connective tissue disease. 61 54
20133348 2010
Genetics of vasculitis. 54 61
20051862 2010
Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial. 54 61
20093349 2010
Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. 61 54
19812889 2010
Analysis of T-cell receptor usage in myeloperoxidase--antineutrophil cytoplasmic antibody-associated renal vasculitis. 54 61
19809783 2010
Henoch-schonlein purpura-a case report and review of the literature. 54 61
20508739 2010
Refractory antineutrophil cytoplasmic antibody-associated vasculitis successfully treated with rituximab: a case report. 61 54
20453447 2010
Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. 61 54
19770659 2010
Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan. 54 61
20173346 2010
Pathogenesis of small vessel vasculitis associated with autoantibodies to neutrophil cytoplasmic antigens: new insights from animal models. 61 54
19823088 2010
Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease. 61 54
19946017 2010
Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis. 61 54
19951419 2009
Immunomodulator agent-related lymphoproliferative disorders. 61 54
19767727 2009
Hypergammaglobulinaemic purpura associated with alcoholic liver cirrhosis. 61 54
20055836 2009
[Henoch-Shönlein purpura]. 61 54
19345173 2009
[Retinal vein occlusion followed by ischemic optic neuropathy with anticardiolipin IgG antibody: a case report]. 61 54
19882933 2009
Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. 61 54
19809051 2009
Autoantibody screen in inflammatory myopathies high prevalence of antibodies to gliadin. 54 61
19758147 2009
High-sensitivity detection of autoantibodies against proteinase-3 by a novel third-generation enzyme-linked immunosorbent assay. 61 54
19758130 2009
Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. 54 61
19714581 2009
Retinoid X receptor beta polymorphisms do not explain functional differences in vitamins D and A response in Antineutrophil cytoplasmic antibody associated vasculitis patients. 61 54
19811264 2009
Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. 61 54
19491223 2009
EUROPLUS ANCA BIOCHIP mosaic: PR3 and MPO antigen microdots improve the laboratory diagnostics of ANCA-associated vasculitis. 61 54
19615371 2009
[Antineutrophil cytoplasmic antibodies and associated diseases]. 61 54
18834675 2009
Lack of association between E148Q MEFV variant and Kawasaki disease. 54 61
19026701 2009
Neutrophil-derived proteinase 3 induces kallikrein-independent release of a novel vasoactive kinin. 54 61
19494315 2009
Correlations between plasma levels of a fibronectin isoform subpopulation and C-reactive protein in patients with systemic inflammatory disease. 54 61
19489687 2009
Myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis with diffuse tubulointerstitial nephritis. 61 54
19557721 2009
Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: relation to azathioprine maintenance treatment and adverse effects. 54 61
19366895 2009
[Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases]. 54 61
19349142 2009
Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. 61 54
19264905 2009
The association of CTLA-4 and CD28 gene polymorphisms with idiopathic ischemic stroke in the paediatric population. 61 54
19284445 2009
Blockade of ICAM-1: a novel way of vasculitis treatment. 54 61
19249285 2009
Circulating neutrophil gelatinase-associated lipocalin: a useful biomarker for assessing disease activity of ANCA-associated vasculitis. 54 61
19181656 2009
Refractory central nervous system vasculitis and gastrocnemius myalgia syndrome in Crohn's disease successfully treated with anti-tumor necrosis factor-alpha antibody. 61 54
18304612 2009
Follow-up of avidity and titer of anti-myeloperoxidase antibodies in sera from patients with primary ANCA-associated vasculitis. 54 61
19301200 2009
Acute Chlamydia pneumoniae infection in the pathogenesis of autoimmune diseases. 61 54
19151119 2009
Review article: The role of CD4(+) T cells in ANCA-associated systemic vasculitis. 61 54
19143940 2009
Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. 61 54
19284577 2009
Expression of tumor necrosis factor receptors on granulocytes in patients with myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated vasculitis. 61 54
19690440 2009
Two types of myeloperoxidase-antineutrophil cytoplasmic autoantibodies with a high affinity and a low affinity in small vessel vasculitis. 61 54
19646343 2009
Giant cell arteritis: A rare cause of posterior vasculitis. 54 61
19668553 2009
Advances in the use of biologic agents for the treatment of systemic vasculitis. 54 61
19077713 2009
Classification of clinical subtypes, patient survival, kidney prognosis, and relapse in patients with MPO-ANCA-associated vasculitis: a single-center experience. 61 54
19521745 2009

Variations for Vasculitis

ClinVar genetic disease variations for Vasculitis:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CCM2 NM_001029835.2(CCM2):c.1297C>T (p.Arg433Trp) SNV Uncertain significance 523540 rs544276945 GRCh37: 7:45115555-45115555
GRCh38: 7:45075956-45075956
2 COL4A2-AS2 , COL4A2 NM_001846.4(COL4A2):c.1776+13A>G SNV Uncertain significance 523445 rs1555330577 GRCh37: 13:111114744-111114744
GRCh38: 13:110462397-110462397

Expression for Vasculitis

Search GEO for disease gene expression data for Vasculitis.

Pathways for Vasculitis

Pathways related to Vasculitis according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
11 11.74 TNFSF13B TNF ICAM1
Show member pathways
13 11.64 PRTN3 MPO ELANE
Show member pathways
Show member pathways
18 11.37 VCAM1 SELE ICAM1
21 10.66 VCAM1 TNF MPO ICAM1

GO Terms for Vasculitis

Cellular components related to Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.11 VWF VCAM1 SERPINB1 SERPINA1 PRTN3 MPO
2 cell surface GO:0009986 9.97 VCAM1 TNF THBD ICAM1 ELANE CX3CL1
3 collagen-containing extracellular matrix GO:0062023 9.86 VWF SERPINB1 SERPINA1 PRTN3 ICAM1 ELANE
4 extracellular region GO:0005576 9.83 VWF TNFSF13B TNF SERPINB1 SERPINA1 PRTN3
5 external side of plasma membrane GO:0009897 9.8 VCAM1 TNF THBD ICAM1 CD40LG
6 membrane raft GO:0045121 9.73 TNF SELE PRTN3 ICAM1
7 azurophil granule lumen GO:0035578 9.63 PRTN3 MPO ELANE CTSG BPI ADA2
8 extracellular space GO:0005615 9.6 VWF VCAM1 TNFSF13B TNF THBD SERPINB1

Biological processes related to Vasculitis according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.95 VWF VCAM1 TNF ICAM1
2 immune response GO:0006955 9.95 TNFSF13B TNF CX3CL1 CTSG CD40LG BPI
3 regulation of immune response GO:0050776 9.92 VCAM1 TNFSF13B ICAM1 CD40LG
4 blood coagulation GO:0007596 9.91 VWF THBD SERPINA1 PRTN3
5 cytokine-mediated signaling pathway GO:0019221 9.91 VCAM1 TNF PRTN3 ICAM1 CX3CL1
6 inflammatory response GO:0006954 9.88 TNF SELE MEFV CX3CL1 CRP CD40LG
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 TNF ICAM1 CX3CL1 CD40LG
8 defense response to bacterium GO:0042742 9.85 TNF MPO ELANE CTSG BPI
9 negative regulation of interleukin-6 production GO:0032715 9.81 TNF CX3CL1 BPI
10 positive regulation of T cell proliferation GO:0042102 9.79 VCAM1 TNFSF13B CD40LG
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 TNF ELANE CX3CL1
12 leukocyte migration GO:0050900 9.77 TNF THBD SELE ICAM1 ELANE
13 hemostasis GO:0007599 9.75 VWF THBD SERPINA1
14 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.74 VCAM1 SELE ICAM1
15 negative regulation of interleukin-1 beta production GO:0032691 9.71 SERPINB1 MEFV CX3CL1
16 defense response to fungus GO:0050832 9.67 MPO ELANE CTSG
17 positive regulation of immune response GO:0050778 9.65 ELANE CTSG
18 negative regulation of fibrinolysis GO:0051918 9.64 THBD APOH
19 negative regulation of lipid storage GO:0010888 9.63 TNF CRP
20 regulation of immunoglobulin production GO:0002637 9.63 TNF CD40LG
21 positive regulation of leukocyte tethering or rolling GO:1903238 9.62 SELE ELANE
22 leukocyte tethering or rolling GO:0050901 9.61 VCAM1 TNF SELE
23 acute inflammatory response to antigenic stimulus GO:0002438 9.59 ICAM1 ELANE
24 positive regulation of I-kappaB phosphorylation GO:1903721 9.58 TNF CX3CL1
25 membrane to membrane docking GO:0022614 9.56 VCAM1 ICAM1
26 antimicrobial humoral response GO:0019730 9.56 PRTN3 ELANE CTSG BPI
27 neutrophil degranulation GO:0043312 9.56 SERPINB1 SERPINA1 PRTN3 MPO ELANE CTSG
28 response to yeast GO:0001878 9.52 MPO ELANE
29 leukocyte migration involved in inflammatory response GO:0002523 9.5 SELE ELANE CX3CL1
30 leukocyte cell-cell adhesion GO:0007159 9.46 VCAM1 SELE ICAM1 CD40LG
31 response to lipopolysaccharide GO:0032496 9.17 VCAM1 THBD SELE MPO ICAM1 ELANE

Molecular functions related to Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.62 TNFSF13B TNF CX3CL1 CD40LG
2 protease binding GO:0002020 9.46 VWF TNF SERPINA1 ELANE
3 tumor necrosis factor receptor binding GO:0005164 9.43 TNFSF13B TNF CD40LG
4 heparin binding GO:0008201 9.35 MPO ELANE CTSG APOH ADA2
5 integrin binding GO:0005178 9.02 VWF VCAM1 ICAM1 CX3CL1 CD40LG

Sources for Vasculitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....